Cure8 research brief
Proactive monitoring of adalimumab levels could help keep drug concentrations therapeutic and reduce loss of response during maintenance therapy for ulcerative colitis.
Patients with UC on adalimumab (patients-on-biologics), their clinicians, and adult IBD patients considering biologic drug-level monitoring.
The article examines measuring adalimumab levels at intervals (proactive TDM) in patients on maintenance therapy. The goal is dose optimization to maintain remission and possibly prevent loss of response.
The report is described as "real-world data," and the available content is an abstract rather than a full paper, so details on study size, methods, and outcomes are not available in the provided text.
This entry is based on an abstract-level, source-provided summary (real-world data) from a journal article; the full paper would be needed to evaluate methods and outcomes before changing care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
